PSYBIO THERAPEUTICS AND MIAMI UNIVERSITY:
SOLVING THE CHALLENGE OF CLINICAL SCALE PRODUCTION
Current methods remain tedious and costly
Involving numerous intermediate separation and puriﬁcation steps resulting in an
the overall yield of 49% from 4-hydroxy indole (Shirota et al., 2003), incurring
an estimated cost of $2000 per gram for pharmaceutical-grade psilocybin
(Fricke et al., 2019).
Platform technology enables rapid generation
Of additional psychoactive compounds with distinct desirable properties.
Utilizing our proprietary platform technology
Our solution is cheaper, faster, cleaner, and greener. Patent-pending
process of using pharmaceutically scalable prokaryotic hosts. Genetic
optimization has resulted in a 32-fold improvement in psilocybin yield.